Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 7 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready
Design Therapeutics Inc. has 9 pending office actions in Biotechnology & Pharmaceuticals. Those matters are distributed across 9 examiners and 7 art units, creating a prosecution portfolio with broad examiner coverage and some art-unit concentration.
KOSAR, ANDREW D is the busiest examiner, with 1 pending matter. No examiner accounts for a large share of the portfolio, so prosecution planning should be coordinated across multiple examiner interactions rather than centered on one recurring relationship.
The spread across 7 art units may require matter-specific claim strategy and docket oversight. A unified review of recurring technical or procedural issues can still help counsel identify opportunities for consistent responses across the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (22%) |
| §102 only | 1 (11%) |
| §112 only | 3 (33%) |
| Double-patenting + other | 2 (22%) |
| Multi-statute (no §101) | 1 (11%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSAR, ANDREW D | 1 | 41.9% | +31.9% |
| KONOPKA, CATHERINE ANNE | 1 | 57.5% | +66.2% |
| MEAH, MOHAMMAD Y | 1 | 70.7% | +42.8% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +36.1% |
| SAMSELL, RILLA MARIE | 1 | 69.1% | +6.4% |
| SAEED, KAMAL A | 1 | 83.8% | +9.8% |
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| VAJDA, KRISTIN ANN | 1 | 83.8% | +11.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18450775 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | SAEED, KAMAL A | — |
| 18260549 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | WILLIS, DOUGLAS M | — |
| 18256864 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | VAJDA, KRISTIN ANN | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18294494 | PROCESS FOR POLYAMIDE SYNTHESIS | PECKHAM, RICHARD GRANT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17759944 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | HAVLIN, ROBERT H | 71d |
| 18726567 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | KOSAR, ANDREW D | — |
| 18600510 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | KONOPKA, CATHERINE ANNE | — |
| 18590521 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | MEAH, MOHAMMAD Y | — |
| 18294494 | PROCESS FOR POLYAMIDE SYNTHESIS | PECKHAM, RICHARD GRANT | — |
| 18260549 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | WILLIS, DOUGLAS M | — |
| 18256864 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | VAJDA, KRISTIN ANN | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1626 | 2 |
| 1625 | 1 |
| 1635 | 1 |
| 1652 | 1 |
| 1627 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18726567 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | KOSAR, ANDREW D | 1625 | §103 | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18600510 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | KONOPKA, CATHERINE ANNE | 1635 | §102§103§112DPOther | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18590521 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | MEAH, MOHAMMAD Y | 1652 | §112 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18294494 | PROCESS FOR POLYAMIDE SYNTHESIS | PECKHAM, RICHARD GRANT | 1627 | §102§112 | Non-Final OA | — | Pending | Feb 01, 2024 |
| 18480353 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | SAMSELL, RILLA MARIE | 1624 | §102§112DP | Non-Final OA | — | Pending | Oct 03, 2023 |
| 18450775 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | SAEED, KAMAL A | 1626 | §103 | Non-Final OA | — | Pending | Aug 16, 2023 |
| 17759944 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | HAVLIN, ROBERT H | 1626 | §102 | Non-Final OA | 71d | Pending | Aug 10, 2023 |
| 18260549 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | WILLIS, DOUGLAS M | 1624 | §112 | Non-Final OA | — | Pending | Jul 06, 2023 |
| 18256864 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | VAJDA, KRISTIN ANN | 1622 | §112 | Non-Final OA | — | Pending | Jun 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDesign Therapeutics Inc. has 9 pending office actions as of October 2026, spread across 7 art units and 9 examiners.
Andrew D Kosar has the most, with 1 of Design Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
